Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 1
2000 3
2001 2
2002 2
2003 2
2004 10
2005 7
2006 13
2007 12
2008 13
2009 13
2010 18
2011 20
2012 18
2013 10
2014 9
2015 14
2016 10
2017 7
2018 4
2019 4
2020 6
2021 8
2022 6
2023 2
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Pkhaladze L, et al. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7476-7485. doi: 10.26355/eurrev_202112_27447. Eur Rev Med Pharmacol Sci. 2021. PMID: 34919250 Free article. Clinical Trial.
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo-Ins) (group B), or OCP plus myo-Ins (group C). ...
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo- …
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial.
El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J. El Taha L, et al. Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:205-212. doi: 10.1016/j.ejogrb.2021.10.029. Epub 2021 Oct 30. Eur J Obstet Gynecol Reprod Biol. 2021. PMID: 34826668 Clinical Trial.
STUDY DESIGN: Seventy women with endometriosis-associated chronic pelvic pain, dysmenorrhoea or both for >6 months were randomized to either dienogest (Visanne) 2 mg/day or monophasic COC (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone) for 24 wee …
STUDY DESIGN: Seventy women with endometriosis-associated chronic pelvic pain, dysmenorrhoea or both for >6 months were randomized to eit …
Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM. Klipping C, et al. Contraception. 2021 Apr;103(4):213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9. Contraception. 2021. PMID: 33428907 Free article. Clinical Trial.
OBJECTIVES: To evaluate the effect on endocrine and metabolic parameters of a new combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP). STUDY DESIGN: Randomized, open-label, controlled, 3-arm, parallel study. ...
OBJECTIVES: To evaluate the effect on endocrine and metabolic parameters of a new combined oral contraceptive (COC) containing estetrol (E4) …
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Foidart JM, Archer DF. Creinin MD, et al. Contraception. 2021 Sep;104(3):222-228. doi: 10.1016/j.contraception.2021.05.002. Epub 2021 May 15. Contraception. 2021. PMID: 34000251 Free article. Clinical Trial.
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. STUDY DESIGN: Women aged 16 to 50 years with a body mass index 35 kg/m(2) enrolled in this multicenter, open-label, 13-cycle, phas …
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DR …
Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G, Senthil Kumar KV, Kulshrestha V, Khadgawat R, Mahey R, Bhatla N. Kachhawa G, et al. Int J Gynaecol Obstet. 2022 Aug;158(2):278-284. doi: 10.1002/ijgo.13971. Epub 2021 Nov 10. Int J Gynaecol Obstet. 2022. PMID: 34624138 Clinical Trial.
METHODS: Seventy young women with PCOS aged 15-24 years with delayed cycles were randomized into two groups and were treated for 6 months with MI + DCI (550 + 150 mg, 3.6:1 ratio) twice a day and CHC (ethinyl estradiol 20 g + drospirenone 3 mg) once a day. RE …
METHODS: Seventy young women with PCOS aged 15-24 years with delayed cycles were randomized into two groups and were treated for 6 months wi …
Bone impact after two years of low-dose oral contraceptive use during adolescence.
Orsolini LR, Goldberg TBL, Caldeirão TD, Cristiane da Silva C, Rizzo ADCB, Biason TP, Teixeira AS, Carvalho Nunes HR. Orsolini LR, et al. PLoS One. 2023 Jun 8;18(6):e0285885. doi: 10.1371/journal.pone.0285885. eCollection 2023. PLoS One. 2023. PMID: 37289781 Free PMC article. Clinical Trial.
The COC1 group used 20 mug Ethinylestradiol (EE)/150 mug Desogestrel and the COC2 group used 30 mug EE/3 mg Drospirenone over a period of two years. These groups were compared to a control group of adolescent non-COC users. ...
The COC1 group used 20 mug Ethinylestradiol (EE)/150 mug Desogestrel and the COC2 group used 30 mug EE/3 mg Drospirenone over a perio …
Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome.
Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Ozdemir S, et al. Int J Gynaecol Obstet. 2008 Oct;103(1):44-9. doi: 10.1016/j.ijgo.2008.05.017. Epub 2008 Jul 16. Int J Gynaecol Obstet. 2008. PMID: 18635183 Clinical Trial.
METHODS: Sixty-three women with PCOS were randomized to receive MPA or ethinyl estradiol plus drospirenone. RESULTS: There were no changes in lipid or carbohydrate metabolism in the MPA group, but serum levels of luteinizing hormone (P<0.001) and total tes …
METHODS: Sixty-three women with PCOS were randomized to receive MPA or ethinyl estradiol plus drospirenone. RESULTS: Th …
A randomized single-blind non-inferiority trial of delayed start with drospirenone-only and ethinyl estradiol-gestodene pills for ovulation inhibition.
Ratanasaengsuang A, Uaamnuichai S, Santibenchakul S, Wongwathanavikrom R, Chaikittisilpa S, Pohthipornthawat N, Taweepolcharoen C, Jaisamrarn U, Phutrakool P. Ratanasaengsuang A, et al. Sci Rep. 2024 Jun 19;14(1):14151. doi: 10.1038/s41598-024-64753-7. Sci Rep. 2024. PMID: 38898193 Free PMC article. Clinical Trial.
We compared the efficacy of 4 mg drospirenone (DRSP) progestin-only pills (POPs) versus combined oral contraceptive pills (COCs) containing 0.02 mg of ethinyl estradiol (EE) and 0.075 mg of gestodene (GS) in ovulation inhibition and inducing unfavorable cervi …
We compared the efficacy of 4 mg drospirenone (DRSP) progestin-only pills (POPs) versus combined oral contraceptive pills (COCs) cont …
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Tfayli H, Ulnach JW, Lee S, Sutton-Tyrrell K, Arslanian S. Tfayli H, et al. J Clin Endocrinol Metab. 2011 May;96(5):1311-9. doi: 10.1210/jc.2010-2547. Epub 2011 Feb 16. J Clin Endocrinol Metab. 2011. PMID: 21325466 Free PMC article. Clinical Trial.
OBJECTIVE: Our objective was to compare the effects of 6 months treatment with drospirenone/ethinyl estradiol (EE) (3 mg/30 mug) vs. rosiglitazone (4 mg) daily on the hormonal and cardiometabolic profiles of overweight/obese adolescents with PCOS. ...Compared …
OBJECTIVE: Our objective was to compare the effects of 6 months treatment with drospirenone/ethinyl estradiol (EE) (3 m …
Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females.
Richter WH, Koytchev R, Kirkov V, Merki G, Colli E, Regidor PA. Richter WH, et al. Contraception. 2020 Feb;101(2):137-143. doi: 10.1016/j.contraception.2019.10.005. Epub 2019 Nov 21. Contraception. 2020. PMID: 31758920 Clinical Trial.
OBJECTIVE: To determine the pharmacokinetics (PK) of drospirenone (DRSP), alone versus in combination with ethinyl estradiol (EE), after single and repeated administration. ...
OBJECTIVE: To determine the pharmacokinetics (PK) of drospirenone (DRSP), alone versus in combination with ethinyl estradio …
189 results